Previsioni

Acquista	1
Mantieni	0
Vendi	0

Notizie Vai al feed delle notizie

Cipher Pharmaceuticals misses Q2 revenue and earnings forecasts, stock rises anyway

Cipher reported Q2 2026 revenue of $12.07 million and adjusted earnings of $0.15 per share, missing consensus estimates. Despite a 10% revenue decline and weaker Natroba sales in the U.S., the company remained highly profitable with an 80% gross margin and a 57% adjusted EBITDA margin and is debt-free. Management cites a Walmart partnership and a new direct-to-patient platform as growth drivers, which helped the stock rise 2.16% in after-hours trading. Risks remain Medicaid pressure on Natroba and dependence on two core products. » Altro su de.investing.com
Cipher Pharmaceuticals beats EPS estimates, slightly misses revenue target

Cipher Pharmaceuticals reported Q4 2025 EPS of CAD 0.51, well above market expectations, while revenue of $12.2 million missed the $12.52 million forecast by 2.4%. Gross margin rose sharply to 81% and adjusted EBITDA increased by 40%, but revenue growth was weighed down by declining licensing revenues. The stock dipped slightly in after-hours trading; management expects strong EPS growth in 2026 and is focusing on expanding the direct-to-consumer platform and pursuing strategic partnerships. Risks remain competitive pressure in the US and uncertainty around licensing revenues. » Altro su de.investing.com
Cipher Pharmaceuticals beats EPS, misses revenue target — shares slip

Cipher Pharmaceuticals reported Q3 2025 earnings per share of $0.21 (vs. expectation $0.1659), thus beating EPS forecasts, while revenue of $12.8 million missed the expected $13.52 million by 5.1%. Net sales rose 24% year over year, adjusted EBITDA increased 79%, and net income for Q3 was $5.5 million. Debt was reduced from $40 million to $8 million, and the company aims to be debt-free by year-end. Cipher plans a direct sales model in early 2026 and is advancing the launch of Natroba in Canada; the stock fell 0.77% after hours. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Cipher Pharmaceuticals ha registrato ricavi pari a 10,30M€ e un utile netto di 3,43M€

(EUR)	giu 2026	YoY
Ricavi	+10,30M	9,27%
Utile lordo	+6,76M	26,84%
Utile netto	+3,43M	31,49%
EBITDA	+5,34M	7,35%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+221,71M€
Numero di azioni	25,39M
Massimo/minimo a 52 settimane	+12,73€ - +7,73€
Dividendi	No
Beta	0,46
Rapporto P/E	+8,92
Rapporto PEG	+0,06
Rapporto P/B	+1,89
Rapporto P/S	+5,24

Profilo aziendale

Cipher Pharmaceuticals Inc. ist als pharmazeutisches Spezialitätenunternehmen in Kanada tätig. Zu seinen Handelsprodukten gehören Epuris (CIP-ISOTRETINOIN), eine Formulierung des Wirkstoffs Isotretinoin zur Behandlung von schwerer Akne; Ozenoxacin zur Behandlung von Impetigo bei Erwachsenen und Kindern; Actikerall zur Behandlung von tastbaren oder mäßig dicken aktinischen Keratosen; Vaniqa, eine verschreibungspflichtige Creme, die das Wachstum unerwünschter Gesichtsbehaarung bei Frauen reduziert; BRINAVESS, ein Medikament zur Behandlung des Sinusrhythmus bei Erwachsenen; und AGGRASTAT, ein intravenös zu verabreichendes Medikament gegen Blutplättchen. Zu den lizenzierten Produkten des Unternehmens gehören CIP-Isotretinoin, Lipofen (CIP-Fenofibrat), eine Formulierung des Wirkstoffs Fenofibrat zur Behandlung von Hyperlipidämie, einer Cholesterinerkrankung, und Conzip/Durela (CIP-Tramadol), eine Formulierung des Wirkstoffs Tramadol zur Behandlung von mäßigen bis mittelstarken Schmerzen. Zu den Produkten in der Pipeline gehören Trevyent, ein gefäßerweiterndes Prostazyklin-Analogon zur Behandlung der pulmonalen arteriellen Hypertonie, CF-101 für schwere Plaque-Psoriasis und rheumatoide Arthritis, MOB-015, eine topische Formulierung von Terbinafin zur Behandlung von Onychomykose, und DTR-001, eine Creme zur Entfernung von Tätowierungen. Cipher Pharmaceuticals Inc. wurde im Jahr 2000 gegründet und hat seinen Hauptsitz in Oakville, Kanada.